Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
Apple App Store Injunction Largely Upheld as Appeals Court Rules on Epic Games Case 
Moore Threads Stock Slides After Risk Warning Despite 600% Surge Since IPO 
SK Hynix Considers U.S. ADR Listing to Boost Shareholder Value Amid Rising AI Chip Demand 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
SpaceX Insider Share Sale Values Company Near $800 Billion Amid IPO Speculation 
ANZ Faces Legal Battle as Former CEO Shayne Elliott Sues Over A$13.5 Million Bonus Dispute 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns 
Rio Tinto Signs Interim Agreement With Yinhawangka Aboriginal Group Over Pilbara Mining Operations 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
Eli Lilly and Company announced on Wednesday, Dec. 27, that it has successfully completed its buyout of the radiopharmaceutical firm that develops cancer treatment, POINT Biopharma Global Inc. The deal is worth about $1.4 billion.
Total Shares Acquired
The multi-million price is for Eli Lilly's acquisition of almost 72.8 million shares of POINT Biopharma. This portion of the shares is said to correspond to more or less 67.97% of the outstanding shares.
As per RTT News, the biopharma firm has a line of clinical and preclinical-stage radioligand therapies that are currently in development. These are for the treatment of cancer diseases, and Eli Lilly is bound to benefit from this as the companies merge. In any case, with the acquisition, Point Biopharma is now set to be delisted from the Nasdaq.
Financial Terms and Other Details of the Deal
Eli Lilly's tender offer to buy all of the issued and outstanding shares of common stock of the Pittsburgh, Pennsylvania-headquartered biopharma company at a purchase price of $12.50 per share without interest has expired right on schedule of 5:00 p.m. on Dec. 22; thus an extension was not necessary. The amount will be paid in cash, less any applicable tax withholding.
"Next-generation radioligand therapies hold great promise for delivering meaningful advances against a range of cancers and we are excited to enter this space through the addition of POINT," Loxo@Lilly's executive vice president and president, Jacob Van Naarden, said in a press release. "We welcome POINT colleagues to Lilly and look forward to working together to build on their work as we create this new capability within Lilly. In time, I hope we can bring several new radioligand therapies to patients with cancer and improve their outcomes."
Goldman Sachs & Co. LLC has been hired as Eli Lilly's exclusive financial advisor, while Kirkland & Ellis LLP is serving as its legal counsel. On the other hand, POINT Biopharma appointed Centerview Partners LLC as its financial advisor and Skadden, Arps, Slate, Meagher & Flom LLP as its legal counsel.
Photo by: Lilly Press Release
